Member Log-in

I forgot my password

Not a Member? Register

Continuing Pneumococcal Vaccination After Gavi Transition in Kenya at Full Price is Cost-effective and Could Save Thousands of Lives

This news release was originally published on EurekAlert. Below is an excerpt from the news release.

Co-led by the London School of Hygiene & Tropical Medicine and the KEMRI-Wellcome Trust Research Program, the Pneumococcal Conjugate Vaccine Impact Study estimated that continuing the vaccine beyond 2022 would prevent – in the first ten years – more than 100,000 children and adults from contracting pneumococcal disease and save the lives of 14,000 children and adults who would otherwise have died.

The cost per year of healthy life saved (US $153) was considerably less than Kenya’s annual gross domestic product (GDP) per person (US $1,790 in 2018), which meets – and far exceeds – the World Health Organization (WHO) GDP-related threshold for ‘very cost-effective’ health interventions.

The researchers say this study offers important evidence for policymakers at what is a crucial time for countries that have to decide whether to continue vaccine programs that have benefited from Gavi’s subsidy of the cost of vaccines once their economies grow and Gavi support diminishes.

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Center for Global Development – Global Immunization and Gavi: Five Priorities for the Next Five Years

Below is an excerpt from the Center for Global Development’s overview note.  Child vaccination remains among the most cost-effective uses of public and aid monies.[1] In a highly contested funding environment where priorities must be set for the allocation of scarce concessional resources, investment in expanding the availability and coverage of cost-effective vaccination must come … Continued

Practitioner Perspectives: 2019 Network-Wide Meeting Interview Series – Côte d’Ivoire Interview on What They Hope to Learn from LNCT

During our network-wide meeting, which took place in Tangerang, Indonesia in July 2019, we sat down with a few participants to hear about their experiences related to topics around their Gavi transition experiences. This interview features the following LNCT members: Interviewer: Alexis Mourou Moyoka, Head Doctor of the EPI, Congo Interviewees: Mamadou Samba, Director General … Continued

Materials from Immunization Economics’ 2019 iHEA Pre-Congress Session Now Available

As part of the 2019 iHEA biennial world congress in Basel, Switzerland, the Immunization Economics Special Interest Group (SIG) organized a pre-congress session on July 13-14. The program, which focused on the generation and use of information surrounding immunization costing, financing, and value of vaccination, included: Featured updates on research findings, methodology, and cases; Concurrent … Continued

Choose a Language